In the midst of shifting political headwinds and a tight funding market, many life sciences companies are considering their M&A exit. Potential acquirers (both strategic and private equity) have plenty of dry powder and are ready to drive transactions to the finish line. However, in positioning themselves as acquisition targets, life sciences companies must carefully consider the impact of their existing strategic collaborations on any potential deal. Often, an existing collaboration can be a strong driver of M&A interest and value, but these relationships can also introduce complexities — making alignment with collaboration partners crucial for a seamless transaction.
Read the full article: Strategic Alignment with Collaboration Partners Is Essential to a Successful Life Sciences M&A Exit //
Source: https://www.lexology.com/library/detail.aspx?g=c41bdc52-fabd-4058-867d-6470761a1124